Onychomycosis (Tinea Unguium) Pipeline Review, H1 2019 Therapeutics Report - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--May 23, 2019--
The “Onychomycosis (Tinea Unguium) - Pipeline Review, H1 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Onychomycosis (Tinea Unguium) - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Onychomycosis (Tinea Unguium) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Onychomycosis (Tinea Unguium) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Onychomycosis (Tinea Unguium) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 7, 2, 2, 1 and 1 respectively.
Onychomycosis (Tinea Unguium) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/v91ngn
View source version on businesswire.com:https://www.businesswire.com/news/home/20190523005414/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Infectious Diseases Drugs
INDUSTRY KEYWORD: HEALTH INFECTIOUS DISEASES
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 05/23/2019 08:58 AM/DISC: 05/23/2019 08:58 AM